It is estimated that in 2021, more than 14,480 new cases of invasive cervical cancer will be diagnosed in the US, and 4,290 women will die from the disease.

ADRX-0706 is a Nectin-4 ADC being evaluated in the Phase 1b portion of an ongoing Phase 1a/b clinical trial (NCT06036121) for the treatment of select advanced solid tumors, including cervical cancer.

Cervical cancer is when abnormal cells in the lining of the cervix grow in an uncontrolled way. The cervix is part of the female reproductive system. It is the opening to the vagina from the womb. The ...

New MRI Technique May Identify Cervical Cancer Early Date: October 22, 2008 Source: Radiological Society of North America Summary: Using high-resolution magnetic resonance imaging with a special ...

Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy. The trial of 502 patients showed Tivdak improved median overall ...

This study looked at diffusion weighted MRI (DW MRI) for cervical cancer. The study was for women with cervical cancer that was still in the neck of the womb (early cervical cancer). This trial was ...

The lone ADC in Sanofi’s pipeline, tusamitamab ravtansine, stems from a partnership with ImmunoGen. The drug targets a protein called CEACAM-5 and it is in development in several types of cancer.

Endometrial and cervical cancers are common cancers in women, said Heather He, MD/PhD, of MD Anderson Cancer Center in Houston, where the study was conducted under the direction of Dr. Iyer and Dr ...